SCPX:NYE-Scorpius Holdings Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.1859

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.40M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

-1.15 (-0.86%)

USD 567.03B
BHVN Biohaven Pharmaceutical Holdin..

-1.08 (-2.81%)

USD 3.39B
HTD John Hancock Tax Advantaged Di..

+0.07 (+0.34%)

USD 2.41B
DNA Ginkgo Bioworks Holdings

-0.03 (-3.98%)

USD 1.68B
RCUS Arcus Biosciences Inc

-0.56 (-3.21%)

USD 1.60B
NUVB Nuvation Bio Inc

-0.09 (-2.64%)

USD 0.80B
ADCT ADC Therapeutics SA

+0.01 (+0.24%)

USD 0.39B
PGP PIMCO Global StocksPLUS & Inco..

+0.03 (+0.39%)

USD 0.32B
ATNM Actinium Pharmaceuticals Inc

-0.05 (-0.51%)

USD 0.29B
CYBN Cybin Inc

N/A

USD 0.28B

ETFs Containing SCPX

XSD SPDR® S&P Semiconductor .. 3.93 % 0.35 %

+0.15 (+0.22%)

USD 1.44B
XSDX:LSE Xtrackers ShortDAX Daily .. 3.91 % 0.00 %

-1.40 (0.22%)

USD 0.19B
DXSN:F Xtrackers - ShortDAX Dail.. 3.91 % 0.00 %

-0.01 (0.22%)

USD 0.19B
DXSN:XETRA Xtrackers - ShortDAX Dail.. 3.91 % 0.00 %

+0.03 (+0.22%)

USD 0.21B
XITK SPDR® FactSet Innovative.. 1.83 % 0.45 %

-0.01 (0.22%)

USD 0.12B
ISMD Inspire Small/Mid Cap Imp.. 0.26 % 0.62 %

-0.07 (0.22%)

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike